The holistic study for immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial compares two treatments for adults recently diagnosed with immune thrombocytopenia (ITP) whose platelet count is very low and hasn't improved with standard steroids. The goal is to find a better way to raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary ITP within the last year.
- Your platelet count is below 30 (measured within the last 2 weeks).
- Standard steroid treatment (dexamethasone or prednisone) did not work or you stopped it due to side effects.
- You have not had certain previous ITP treatments like rituximab, other immune suppressants, dapsone, danazol, chemotherapy (except vincristine as rescue), or spleen removal.
- You are not pregnant, breastfeeding, or planning to become pregnant without using effective birth control for at least 12 months if assigned to rituximab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—avatrombopag and all-trans retinoic acid—in adults with persistent or chronic immune thrombocytopenia (ITP) whose platelet levels stay low despite prior treatments. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
This trial tests a drug called belantamab mafodotin for adults with primary immune thrombocytopenia (ITP) whose platelet levels stayed low after trying steroids and another treatment like TPO-RA or rituximab. The goal is to see if it safely raises platelet counts.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
Hear when a new Thrombocytopenia Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.